A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer

Trial Profile

A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Trastuzumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ToGA
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Nov 2012 Planned number of patients changed from 500 to 584.
    • 23 Sep 2011 An exploratory analysis investigating health-related quality of life in a subgroup of patients with high HER2 expression levels has been reported at the 2011 European Multidisciplinary Cancer Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top